BRAF and melanoma: Combined MAPK targeting via cobimetinib (MEK1/2 inhibitor) and dabrafenib (BRAF inhibitor), a clinical approach used to abrogate rapid acquired resistance to MAPK targeting resulted in deeper and more prolonged responses than monotherapy AZD6244 in BRAF PTEN melanoma (Supplementary Fig. S4A).